← Eichor
Study identifier: NCT06623318 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

IV Ensure in Patients Receiving OPAT

Condition: Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates  ·  Sponsor: IV Ensure

PhaseNA
Planned participants90
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of remote therapeutic monitoring is to provide oversight and evaluation of patients receiving IV medications in the home setting post-acute. The goal is to improve patient outcomes and decrease re-admission rates for related diagnoses due to poor adherence. Remote therapeutic monitoring provides data used in the determination of dates, times, and duration of doses administered in the home setting to support real-time intervention by dedicated care managers to support improved adherence with prescribed dosing regiments. The objectives of the study are to: 1. Determine adherence rates for IV medications administered in the home. 2. Assess re-admission against adherence rates.

This description comes directly from the study's public registry record.

Talk to the study team

Mitchell T Berenson, MPH  ·  214-924-6951  ·  mitchell@ivensure.com

Jacob K Dozier, BGS  ·  903-244-4842  ·  jacob.dozier@ivensure.com

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Oklahoma Health Sciences CenterOklahoma City, Oklahoma, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06623318